Emmaus Life Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMMA research report →
Companywww.emmausmedical.com
Emmaus Life Sciences, Inc. , a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
- CEO
- Willis C. Lee
- IPO
- 2000
- Employees
- 34
- HQ
- Torrance, CA, US
Price Chart
Valuation
- Market Cap
- $808.57K
- P/E
- -0.10
- P/S
- 0.07
- P/B
- -0.01
- EV/EBITDA
- -598.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.35%
- Op Margin
- 3.22%
- Net Margin
- -70.65%
- ROE
- 13.78%
- ROIC
- -1.65%
Growth & Income
- Revenue
- $12.45M · -25.22%
- Net Income
- $-7,492,000 · -16.10%
- EPS
- $-0.12 · -20.00%
- Op Income
- $231.00K
- FCF YoY
- 99.48%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 9.42
- Avg Volume
- 33.72K
Get TickerSpark's AI analysis on EMMA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | DU HENRY HUY | other | 0 |
| Oct 1, 24 | Kuwahara Jon | other | 0 |
| Sep 16, 24 | Lim Seah H. | buy | 20,000 |
| Feb 29, 24 | LEE WILLIS C | buy | 77,000 |
| Feb 28, 24 | LEE WILLIS C | buy | 15,000 |
| Feb 27, 24 | LEE WILLIS C | buy | 10,000 |
| Feb 26, 24 | LEE WILLIS C | buy | 13,200 |
| Feb 1, 24 | Zwicker Ian Harvey | other | 100,000 |
| Feb 1, 24 | ZEN Wei Peu | other | 100,000 |
| Feb 1, 24 | Lim Seah H. | other | 100,000 |
Our EMMA Coverage
We haven't published any research on EMMA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EMMA Report →